Firm intentionHealthcare5 November 2026

Brains Therapeutics Corp. to acquire Brains Bioceutical Corp.

Verified deal facts, source-backed narrative, and the Exit Mode founder lens for SME readers preparing to sell.

Deal facts

Buyer
Brains Therapeutics Corp.
Target
Brains Bioceutical Corp.
Deal value
USD 750,000,000
Announced
5 November 2026
Status
Firm intention
Sector
Healthcare
Country
Canada
Consideration
shares, earn-out
What we know

Armada Acquisition Corp. III, a Cayman Islands SPAC, signed a Business Combination Agreement on October 31, 2026 with Armada Sponsor III, LLC, Brains Bioceutical Corp. and Brains Therapeutics Corp. Brains Bioceutical is a British Columbia company, and Brains Therapeutics (called PubCo in the filing), also incorporated in British Columbia, will become the listed parent. The 8-K, signed November 5, 2026, says the SPAC and Brains issued a joint press release that day announcing the agreement.

Brains Bioceutical is a pharmaceutical company combining an established EU-GMP manufacturing and regulatory platform with proprietary and partnered drug-development programs focused on cannabinoid-based therapeutics. Through its subsidiary BSPG Laboratories Limited, it operates an MHRA-inspected and registered API manufacturing facility in Kent, England. It is headquartered in Vancouver.

Brains security holders will receive newly issued PubCo shares, rollover equity awards and rollover warrants. These are attributable to a transaction value starting from a $750.0 million Enterprise Value. That figure is reduced by the estimated closing balance sheet adjustment and by Company expenses above $10.0 million, and increased by SPAC transaction expenses above $10.0 million. The result is divided by a $10.20 reference value per share. The filing also provides for 14,705,882 earnout shares, issued at closing and held in escrow. Half are released if PubCo's volume-weighted average price reaches $12.50 and the other half at $15.00, for at least 20 trading days within any 30-trading-day period between six months and three years after closing. A change of control at or above those prices also triggers release.

The mechanics run in two steps. A Cayman merger first makes the SPAC a wholly owned subsidiary of PubCo, with each SPAC Class A share exchanged for one PubCo share. On the closing date, a PubCo subsidiary then amalgamates with Brains under a British Columbia plan of arrangement, and Brains becomes a wholly owned PubCo subsidiary. Closing conditions include SPAC shareholder approval, approval of the arrangement by holders of not less than two-thirds of the Company common shares present in person or represented by proxy at the Company shareholders meeting, interim and final orders from the Supreme Court of British Columbia, an effective Form F-4 registration statement and approval of PubCo's initial listing application on Nasdaq or another agreed exchange. They also include PubCo having at least $5,000,001 of consolidated net tangible assets after the transactions, and dissent rights exercised by holders of less than 5.0% of Company shares. The parties are to seek up to $100.0 million of transaction financings. Either the SPAC or Brains may terminate if closing has not occurred by June 30, 2027.

The archive tags include an earn-out. Compare completion cash, deferred payments and earn-outs before treating a headline amount as proceeds. Check the underlying announcement for the actual conditions; tags are not a complete payment schedule.

Deal timeline

1 update
  1. Firm intention

    Brains Therapeutics Corp. firm intention to acquire Brains Bioceutical Corp.

    Item 1.01 Entry into a Material Definitive Agreement. Business Combination Agreement General On October 31, 2026, Armada Acquisition Corp. III, a Cayman Islands exempted company (“ SPAC ”), entered into a Business Combination Agreement (the “ Business Combination Agreement ”) with Armada Sponsor III, LLC, a Delaware limited liability company (the “ Sponsor ”), Brains Bioceutical Corp., a company e

    Source

For business owners

What would selling your own business involve?

Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.

Guides are free to read. Free tools require email access; indicative results are not professional advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

Similar deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

Buyer history

Brains Therapeutics Corp.

See every published Exit Mode archive entry where this buyer appears.

View buyer profile

Methodology

How this page is built

Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.

Back to the archive